Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/269480
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Eicosanoid signalling blockade protects middle-aged mice from severe COVID-19 |
Autor: | Wong, Lok-Yin Roy; Zheng, Jian; Wilhelmsen, Kevin; Li, Kun; Ortiz, Miguel E.; Schnicker, Nicholas J.; Thurman, Andrew; Pezzulo, Alejandro A.; Szachowicz, Peter J.; Li, Pengfei; Pan, Ruangang; Klumpp, Klaus; Aswad, Fred; Rebo, Justin; Narumiya, Shuh; Murakami, Makoto; Zúñiga Lucas, Sonia CSIC ORCID ; Solá Gurpegui, Isabel CSIC ORCID ; Enjuanes Sánchez, Luis CSIC ORCID ; Meyerholz, David K.; Fortney, Kristen; McCray, Paul B.; Perlman, Stanley | Fecha de publicación: | 5-may-2022 | Editor: | Nature Publishing Group | Citación: | Nature 605: 146-151 (2022) | Resumen: | Coronavirus disease 2019 (COVID-19) is especially severe in aged populations1. Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are highly effective, but vaccine efficacy is partly compromised by the emergence of SARS-CoV-2 variants with enhanced transmissibility2. The emergence of these variants emphasizes the need for further development of anti-SARS-CoV-2 therapies, especially for aged populations. Here we describe the isolation of highly virulent mouse-adapted viruses and use them to test a new therapeutic drug in infected aged animals. Many of the alterations observed in SARS-CoV-2 during mouse adaptation (positions 417, 484, 493, 498 and 501 of the spike protein) also arise in humans in variants of concern2. Their appearance during mouse adaptation indicates that immune pressure is not required for selection. For murine SARS, for which severity is also age dependent, elevated levels of an eicosanoid (prostaglandin D2 (PGD2)) and a phospholipase (phospholipase A2 group 2D (PLA2G2D)) contributed to poor outcomes in aged mice3,4. mRNA expression of PLA2G2D and prostaglandin D2 receptor (PTGDR), and production of PGD2 also increase with ageing and after SARS-CoV-2 infection in dendritic cells derived from human peripheral blood mononuclear cells. Using our mouse-adapted SARS-CoV-2, we show that middle-aged mice lacking expression of PTGDR or PLA2G2D are protected from severe disease. Furthermore, treatment with a PTGDR antagonist, asapiprant, protected aged mice from lethal infection. PTGDR antagonism is one of the first interventions in SARS-CoV-2-infected animals that specifically protects aged animals, suggesting that the PLA2G2D–PGD2/PTGDR pathway is a useful target for therapeutic interventions. | Versión del editor: | https://doi.org/10.1038/s41586-022-04630-3 | URI: | http://hdl.handle.net/10261/269480 | DOI: | 10.1038/s41586-022-04630-3 | ISSN: | 0028-0836 | E-ISSN: | 1476-4687 |
Aparece en las colecciones: | (PTI Salud Global) Colección Especial COVID-19 (CNB) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
accesoRestringido.pdf | 15,38 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
SCOPUSTM
Citations
63
checked on 13-mar-2024
WEB OF SCIENCETM
Citations
57
checked on 27-feb-2024
Page view(s)
34
checked on 28-mar-2024
Download(s)
6
checked on 28-mar-2024
Google ScholarTM
Check
Altmetric
Altmetric
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.